BIO 2014: Post-Myriad patent rejections 'incredibly case-specific'
26-06-2014
Giordano Aita / Shutterstock.com
The American public's access to new and effective medicines could be at risk as a result of the US Supreme Court's decisions in the Prometheus and Myriad cases, and the resulting guidance for examiners from the US Patent and Trademark Office (USPTO), according to a report presented to the 2014 BIO International Convention in San Diego today (Wednesday).
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
BIO 2014, Bloomberg BNA, USPTO, Prometheus, Myriad